Navigation Links
Estrogen plus progestin use linked with increased breast cancer incidence and mortality
Date:3/29/2013

Estrogen plus progestin use is linked with increased breast cancer incidence. In addition, prognosis is similar for both users and nonusers of combined hormone therapy, suggesting that mortality from breast cancer may be higher for hormone therapy users as well, according to a study published March 29 in the Journal of the National Cancer Institute.

In the Women's Health Initiative (WHI) randomized trial, estrogen plus progestin was associated with an increase in both breast cancer incidence and mortality. However, most observational studies have linked estrogen plus progestin with more positive outcomes.

In order to determine the differences between the WHI trial and other observational studies, Rowan T. Chlebowski, M.D., Ph.D., Los Angeles Biomedical Research Institute (LA BioMed) lead researcher and colleagues, looked at postmenopausal women with no prior hysterectomy with negative mammograms within two years who were either users or non-users of estrogen and progestin combined therapy.

The researchers found that breast cancer incidence was higher in estrogen plus progestin users than incidence in nonusers. Women who started hormone therapy closer to menopause had a higher breast cancer risk with a weakening influence as the time from menopause increased.

"Because survival after breast cancer diagnosis did not differ between estrogen plus progestin users and nonusers, the higher breast cancer incidence of those using estrogen plus progestin may lead to increased breast cancer mortality on a population basis," the authors write.

In an accompanying editorial, Catherine Schairer, Ph.D., and Louise A. Brinton, Ph.D., both of the National Cancer Institute, write that questions remain about whether the data analyzed from the WHI observational study resolves the differences in tumor prognosis and tumor characteristics when compared to the WHI randomized trial. They write that, "In general, tumors in estrogen plus progestin users in the WHI Observational Study were not significantly different from those in non-hormone users with regard to number of positive lymph nodes or tumor size, but were more likely to be well differentiated and positive for hormone receptors, findings which are similar to other observational studies." This, however, did not translate into a survival benefit. They recommend further analyses in this and other datasets of currency and duration of hormone use in relationship to tumor development to fully resolve the issue of tumor characteristics associated with estrogen plus progestin therapy.


'/>"/>

Contact: Zachary Rathner
Zachary.Rathner@oup.com
919-677-2697
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Estrogen helps keep joint pain at bay after hysterectomy
2. Maturitas publishes clinical guide on low-dose vaginal estrogens for vaginal atrophy
3. Genetic markers for testosterone and estrogen level regulation identified
4. BUSM researchers identify genetic markers for testosterone, estrogen level regulation
5. Early-onset baldness in African-American men may be linked to prostate cancer
6. Cedars-Sinai study: Obesity may be linked to microorganisms living in the gut
7. Higher soy intake prior to lung cancer diagnosis linked to longer survival in women
8. Certain Lifestyle Factors Linked to Arthritis in Study Patients
9. Desire to Succeed Linked to Better Grades in College
10. Smokefree workplaces linked to smokefree homes in India
11. Energy Drinks Linked to Changes in Heart Rhythm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 09, 2016 , ... "I have gout, and I wanted to treat it ... is meant to relieve gout and pain caused by varicose veins. I drank it ... time. It relieved what VA doctors called the worst sinusitis case they'd seen and ...
(Date:12/9/2016)... ... December 09, 2016 , ... Sober ... anniversary with the grand opening of the Sober College Robert Pfeifer Memorial Learning ... days, December 2-3, and was attended by an overwhelming amount of alumni, family, ...
(Date:12/9/2016)... New York, NY (PRWEB) , ... December 09, 2016 , ... ... that raises awareness for organ transplantation while encouraging readers to sign up as an ... for a lifesaving organ transplant. , An organ donor can save up to ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... whiteboard display solutions, proudly announced today that a new solution for Emergency Departments ... fit in the tight space in Emergency Department examination rooms, and with a ...
(Date:12/9/2016)... ... 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) ... summer of 2016. The program was made possible by a Pennsylvania Department of ... Health and Human Services Administration. The broadcast, Use Your Head: Properly Managing ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... LONDON , Dec. 8, 2016 ... Summary GlobalData,s new report, "Australia Glaucoma ... market data on the Australia Glaucoma Surgery Devices ... US dollars, volume (in units) and average prices ... The report also provides company shares and ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... largest share of the market in 2016 and is ... can be attributed to a large number of surgical ... hold the largest share in the patient temperature management ... such as reducing loss of blood during surgeries, lowering ...
(Date:12/8/2016)... Research and Markets has announced the addition ... Adhesion Type, Application, Usability - Forecast to 2025" report to ... , , ... poised to grow at a CAGR of around 3.2% from 2015 ... witnessing include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research ...
Breaking Medicine Technology: